Tag: Renal cell carcinoma

Decades ago, a painkiller called phenacetin was conclusively linked to kidney and urinary tract cancers, leading to its ban in the US in 1983. The question of what medications cause kidney tumors is not limited to historical drugs, as research continues to explore associations between long-term use of modern medications and renal cancer risk.

In October 2023, the U.S. Food and Drug Administration (FDA) approved the first generic versions of the targeted cancer therapy Votrient (pazopanib), marking a significant milestone for patients and healthcare providers. This development followed the expiration of key patents, paving the way for more affordable treatment options.

Pazopanib, marketed under the brand name Votrient, has demonstrated significant efficacy in treating specific types of advanced cancers. Approved by the U.S. Food and Drug Administration (FDA) for both advanced renal cell carcinoma and advanced soft tissue sarcoma, this medication is a powerful component of targeted therapy regimens.